Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Artivion, Inc. (NYSE:AORT). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Artivion stock on August 20th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
- Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
- Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
- Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
- Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
- Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
- Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
- Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
- Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
- Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.
Artivion Stock Up 1.9%
AORT stock opened at $25.13 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.47 and a quick ratio of 2.51. The business has a fifty day moving average price of $26.27 and a 200-day moving average price of $28.78. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The stock has a market capitalization of $1.23 billion, a P/E ratio of -358.92 and a beta of 1.25.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on AORT. Weiss Ratings lowered shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Stifel Nicolaus set a $45.00 price objective on Artivion in a report on Monday, June 1st. Needham & Company LLC reiterated a “buy” rating and set a $44.00 price objective on shares of Artivion in a research report on Monday, July 20th. Canaccord Genuity Group increased their target price on Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Finally, Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.83.
Get Our Latest Stock Report on Artivion
Insider Activity
In other Artivion news, SVP Andrew M. Green sold 11,480 shares of Artivion stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $24.97, for a total transaction of $286,655.60. Following the transaction, the senior vice president owned 40,160 shares of the company’s stock, valued at $1,002,795.20. The trade was a 22.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James P. Mackin sold 70,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the transaction, the chief executive officer owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. The trade was a 7.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 90,460 shares of company stock valued at $2,557,366 in the last ninety days. Corporate insiders own 6.30% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in AORT. BlackRock Inc. bought a new position in Artivion in the 2nd quarter worth $149,965,000. Conestoga Capital Advisors LLC bought a new stake in Artivion during the first quarter valued at about $43,044,000. California State Teachers Retirement System increased its position in Artivion by 2,086.7% in the second quarter. California State Teachers Retirement System now owns 1,119,860 shares of the company’s stock worth $25,163,000 after buying an additional 1,068,647 shares in the last quarter. Summit Partners Public Asset Management LLC purchased a new stake in Artivion in the fourth quarter worth about $39,401,000. Finally, Invesco Ltd. raised its stake in shares of Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after buying an additional 748,119 shares during the period. 86.37% of the stock is currently owned by institutional investors.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Artivion
Artivion, Inc is a medical device company focused on developing and supplying products used in cardiac and vascular surgery. The company’s portfolio includes implantable devices, surgical products and preservation technologies designed to treat diseases of the heart and aorta.
Its products include the On-X mechanical heart valve, aortic stent grafts and surgical grafts, as well as BioGlue Surgical Adhesive and other products used to control bleeding and reinforce tissue during cardiovascular procedures.
See Also
- Five stocks we like better than Artivion
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
